

December 12, 2025

VIA RESS

Mr. Ritchie Murray
Acting Registrar
Ontario Energy Board
27th Floor - 2300 Yonge Street
Toronto, Ontario M4P 1E4

Dear Mr. Murray:

Re: EB-2025-0297: Application by Ontario Power Generation Inc. (“OPG”) and DNNP LP by its general partner, DNNP GP Inc., (together, the “Applicants”) for an order or orders relating to payment amounts for prescribed generating facilities (the “Application”) – Request for confidential treatment of information in pre-filed evidence

The Applicants filed the Application on December 12, 2025. In accordance with Rule 10 of the Ontario Energy Board’s (“**OEB**” or the “**Board**”) *Rules of Practice and Procedure* and the OEB’s *Practice Direction on Confidential Filings* (the “**Practice Direction**”). The Applicants hereby requests the OEB’s approval to (i) permanently redact from the public record information that is non-relevant and/or (ii) treat as confidential, certain information included in the Application (collectively, the “**Confidential Information**”).

The Confidential Information is identified in “**Appendix A**”, which provides the basis for the Applicants’ request for confidential treatment, in accordance with Parts 5.1.4 and 11.1.2 of the Practice Direction. All proposed Confidential Information has been redacted in the public version of the Application filed with the OEB.

The Applicants have attached “**Appendix B**” – excluded from the public version of this letter – which includes the confidential (non-redacted) versions of the relevant documents. To this end, the documents that comprise “**Appendix B**”, are marked “Confidential” or “Confidential – Not Relevant”, or both, as applicable, and include highlights for the specific portions of the documents that contain the Confidential Information. In “**Appendix B**”, where appropriate, information for which the Applicants seek confidential treatment on the record has been marked for redaction with a red box (or shaded red, for excel tables). The Applicants applied blue ‘marked-for-redaction’ boxes for non-relevant information, and purple ‘marked-for-redaction’ boxed for information that if disclosed may give rise to liability under securities laws, both of which the Applicants seek to permanently redact from the OEB record.

OPG is a reporting issuer under Canadian provincial securities law, and as such, may be subject to liability (and securities regulatory proceedings) in relation to forward-looking disclosures of financial performance, referred to as “financial outlook”. OPG requests the permanent redaction of the Confidential Information marked for redaction with a purple box on this basis. Similar information was permanently redacted by the OEB in EB-2020-0290 on these grounds.¹ In “**Appendix A**”, a detailed justification for each such proposed permanent redaction is included. In the alternative, and to the extent the OEB does not grant one or more of OPG’s permanent redaction requests, OPG asks that such information be accorded confidential treatment on the basis that it is commercially sensitive information as more particularly set out in “**Appendix A**”.

Lastly, in addition to the requests in this letter, the Applicants wish to advise that certain Confidential Information in “**Appendix B**” concerns Canada Infrastructure Bank debt terms, and is the same type of information that was subject to specific confidentiality protections in the OEB’s Generic Cost of Capital proceeding (EB-2024-0063). In that proceeding, the information in question was not made available to certain participants even if a Declaration and Undertaking was filed.² Depending on the requests for intervenor status that are filed, OPG may seek similar protections in this proceeding. The Applicants will promptly advise the OEB of any such requests following the filing of requests for intervenor status.

Should the OEB require any further information or clarification as to the requests made herein, please contact the Applicants or their legal counsel as required.

Respectfully submitted,



Evelyn Wong

cc: Aimee Collier (OPG) via e-mail
Charles Keizer (Torys LLP) via e-mail

¹ EB-2020-0290 (Decision on Confidentiality, June 8, 2021).

² In EB-2024-0063 (Decision on Confidentiality, December 9, 2024), the OEB did not require the CIB debt terms to be made available to utility participants, even if a Declaration and Undertaking had been filed.

Appendix A – Table of Redactions

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A1-4-1, Attachment 4, Summaries of Internal Audits Completed Since Q4 2020	Pages 1-2, 9-10, 41, 80-81	No	Confidential Treatment	<p>Public Security and Cybersecurity: The information redacted consists of summaries of internal audits since Q4 of 2020 that contain report ratings for security and cybersecurity issues, specific findings with respect to vulnerabilities, and management action plans.</p> <p>The redacted information pertains exclusively to public security and cybersecurity of OPG assets. It identifies specific vulnerabilities, the scale of security and cybersecurity problems, and OPG’s controls and action plan to address such vulnerabilities. Public disclosure of this information could result in malicious actors acquiring knowledge and insights into OPG’s security and cybersecurity systems and status, the scale and nature of established issues, and defensive mechanisms involved, such as OPG’s mitigation or remediation strategy and action plan to address vulnerabilities. As a result, disclosure could adversely impact the security of OPG’s facilities and OPG’s cybersecurity systems and would increase the risk of exploiting this information for malicious purposes (Practice Direction, Appendix A, Part (c)).</p> <p>Previous Treatment: The OEB has previously determined that information related to internal audit findings regarding OPG’s cybersecurity systems and the security of OPG’s facilities should be subject to confidential treatment (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 18-19, 22) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 1	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial information wholly related to Atura Power (“Atura”), an unregulated subsidiary of OPG engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and Atura. If disclosed on the public</p>

¹ Types of Requests: Requests for (1) Confidential Treatment; (2) Permanent Redaction for Non-Relevance; and (3) Permanent Redaction – Securities Laws.

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>record it could prejudice Atura’s competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that certain similar information in OPG’s Business Plan related to OPG’s unregulated business or that of its subsidiaries is not relevant to OPG’s payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 2	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG’s unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record it could prejudice OPG’s competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG’s Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 3	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and financial information wholly related to Atura Power, Eagle Creek Renewable Energy, and Laurentis Energy Partners, all of which are unregulated subsidiaries of OPG engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information consists of commercially sensitive information and confidential financial information not available to the public that is treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 3	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial, financial, and production information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG’s Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 4	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG’s unregulated business and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG’s competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG’s Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 7	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 7	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and financial information wholly related to OPG's unregulated subsidiaries engaged in competitive business activity, and OPG's unregulated assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information consists of commercially sensitive information and confidential financial information not available to the public that is treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 8	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 9	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 9	Yes	Permanent Redaction – Securities Laws	<p>Commercially Sensitive Information, Non-public Forward-looking Financial Information: This information proposed for redaction consists of non-public, forward-looking financial information regarding potential future debt and equity issuances by OPG. OPG consistently treats this information as confidential financial information and confidential commercially sensitive information. As a reporting issuer, OPG may be subject to liability (and securities regulatory proceedings) in relation to forward-looking disclosures of financial performance, referred to as "financial outlook" (Practice Direction, Appendix A, Parts (a)(i) and (b); Appendix B, Part 9).</p> <p>Previous Treatment: The OEB has permanently redacted similar information from OPG's then current Business Plan in previous</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				proceedings (EB-2020-0290, Decision on Confidentiality, June 8, 2021, pp. 2-3) (Practice Direction, Appendix A, Part (e)).
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 9	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and financial information wholly related to Atura Power and Eagle Creek Renewable Energy, both of which are unregulated subsidiaries of OPG engaged in competitive business activity, and OPG's unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that certain similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 10	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG’s Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 11	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking production information wholly related to unregulated subsidiaries of OPG engaged in competitive business activity and OPG’s unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding. The comingled total production information is marked for permanent redaction as it would otherwise enable the reverse engineering of the unregulated information (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries’ competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG’s Business Plan related to OPG’s unregulated business or that of its subsidiaries is not relevant to OPG’s payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 11	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: This information proposed for redaction consists of production information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 12	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial information wholly related to OPG's unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG. If disclosed on the public record, it could prejudice OPG's competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 13	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and production information wholly related to Atura Power ("Atura"), an unregulated subsidiary of OPG engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and Atura. If disclosed on the public record, it could prejudice OPG's and Atura's competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 15	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: This information proposed for redaction consists of commercial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 15	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and production information wholly related to Atura Power ("Atura"), an unregulated subsidiary of OPG engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and Atura. If disclosed on the public record, it could prejudice OPG's and Atura's competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Pages 16-17	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial, financial and headcount information wholly related to OPG's unregulated subsidiaries engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding. The total Ontario-Based Headcount information is marked for permanent redaction as it would otherwise enable the reverse engineering of the subsidiary headcount information (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Pages 16-17	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: This information proposed for redaction consists of headcount information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Pages 18-19	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 21	No	Permanent Redaction for Non-Relevance	Non-relevant: This information proposed for redaction consists of forward-looking commercial and financial information wholly related to OPG's unregulated subsidiaries engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding. The total Capital Expenditures information

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>is marked for permanent redaction as it would otherwise enable the reverse engineering of the subsidiary information (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 21	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 27, 30	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial, financial, and production information wholly related to OPG’s unregulated subsidiaries engaged in competitive business activity and OPG’s unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG’s and its subsidiaries’ competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that certain similar information in OPG’s Business Plan related to OPG’s unregulated business or that of its subsidiaries is not relevant to OPG’s payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 31	Yes	Permanent Redaction – Securities Laws	<p>Commercially Sensitive Information, Non-public Forward-looking Financial Information: This information proposed for redaction consists of non-public, forward-looking financial information regarding potential future debt and equity issuances by OPG. OPG consistently treats this information as confidential financial information and confidential commercially sensitive information. As a reporting issuer, OPG may be subject to liability (and securities regulatory proceedings) in relation to forward-looking disclosures of financial performance, referred to as “financial outlook” (Practice Direction, Appendix A, Parts (a)(i) and (b); Appendix B, Part 9).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Previous Treatment: The OEB has permanently redacted similar information from OPG's then current Business Plan in previous proceedings (EB-2020-0290, Decision on Confidentiality, June 8, 2021, pp. 2-3) (Practice Direction, Appendix A, Part (e)).
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Pages 33-36	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business (including unregulated subsidiaries) and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Pages 33-36	Yes	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking financial information wholly related to unregulated subsidiaries of OPG engaged in competitive business activity and OPG's unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Financial Statement of Unregulated Subsidiary: This information includes the non-public financial statement information of Atura Power,</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Eagle Creek Renewable Energy, and Laurentis Energy Partners, all of which are subsidiaries of OPG engaged in competitive business activity and is presumptively confidential on this basis. (Practice Direction, Appendix B, Part 5).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 36	Yes	Permanent Redaction – Securities Laws	<p>Commercially Sensitive Information, Non-public Forward-looking Financial Information: This information proposed for redaction consists of non-public, forward-looking financial information regarding potential future debt and equity issuances by OPG. OPG consistently treats this information as confidential financial information and confidential commercially sensitive information. As a reporting issuer, OPG may be subject to liability (and securities regulatory proceedings) in relation to forward-looking disclosures of financial performance, referred to as "financial outlook" (Practice Direction, Appendix A, Parts (a)(i) and (b); Appendix B, Part 9).</p> <p>Previous Treatment: The OEB has permanently redacted similar information from OPG's then current Business Plan in previous proceedings (EB-2020-0290, Decision on Confidentiality, June 8, 2021, pp. 2-3) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 37	No	Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking production and headcount information wholly related to OPG's unregulated subsidiaries engaged in competitive business activity and unregulated business. It is therefore not relevant to the determination of payment amounts in this proceeding. The total Ontario-Based Headcount and Total SBG Losses information is marked for permanent redaction as it would otherwise enable the reverse engineering of the subsidiary headcount and Contracted SBG loss information (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 37	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: This information proposed for redaction consists of headcount information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 38	Yes	Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and financial information wholly related to OPG's unregulated subsidiaries engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding. The total Capital Expenditures information is marked for permanent redaction as it would otherwise enable the reverse engineering of the subsidiary information (Practice Direction, Part 11).</p> <p>Financial Statement of Unregulated Subsidiary: This information includes the non-public financial statement information of Atura Power, Eagle Creek Renewable Energy, Laurentis Energy Partners, and PowerON Energy Solutions, all of which are subsidiaries of OPG engaged in competitive business activity and is presumptively confidential on this basis. (Practice Direction, Appendix B, Part 5).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 38	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of financial information reflecting the combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 1, 2025-2031 Business Plan	Page 39	No	Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking production forecast information wholly related to OPG's unregulated subsidiaries engaged in competitive business activity and OPG's unregulated assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public,</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>and treated as confidential by OPG and its subsidiaries. If disclosed on the public record, it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 2, 2025-2031 Business Planning Schedule and Assumptions	Page 9	No	Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking commercial and operational information wholly related to OPG's unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG. If disclosed on the public record, it could prejudice OPG's competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 3, OPG Business Plan Targets	Page 1	No	Confidential Treatment	<p>Commercially Sensitive Information, Confidential Financial Information and Competitive Prejudice: This information proposed for redaction consists of commercial and financial information reflecting the</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>combined regulated and unregulated assets and business of OPG. This information is confidential because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the disclosure of information related to OPG's unregulated business and facilities. OPG consistently treats information relating to its unregulated business as confidential financial information and confidential commercially sensitive information. If disclosed on the public record, it could prejudice OPG's competitive position with respect to those assets and business (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to the combined regulated and unregulated business and assets of OPG is confidential (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021 at p. 9; EB-2016-0152, Procedural Order No. 3, November 1, 2016 at pp. 3-4; EB-2013-0321, Procedural Order No. 4, March 21, 2014 at p. 6; and EB-2010-0008, Procedural Order No. 3, July 21, 2010, p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit A2-2-1, Attachment 3, OPG Business Plan Targets	Page 2	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking financial information wholly related to OPG's unregulated business and assets. It is therefore not relevant to the determination of payment amounts in this proceeding. The total Capital Expenditures information is marked for permanent redaction as it would otherwise enable the reverse engineering of the subsidiary information (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: This information is commercially sensitive, not available to the public, and treated as confidential by OPG. If disclosed on the public record, it could prejudice OPG's competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information in OPG's Business Plan related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p. 6; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p. 5) (Practice Direction, Appendix A, Part (e)).
Exhibit B1-1-1, Chart 2	Lines 1-3, 13-14	No ²	Confidential Treatment	<p>Commercially Sensitive Information: The redacted information consists of OPG's forecasted inventory quantities, costs, and unit prices for uranium concentrate during the upcoming rate period. These forecasted prices are based in part on the price that OPG has agreed to with third party vendors under the terms of its current agreements, which are presumptively confidential as unit prices (Practice Direction, Appendix B, Part 1). Disclosing this information will reveal OPG's expected price for these services, which can compromise the ongoing vendor bid process and OPG's ability to negotiate competitive pricing for the services in question. (Practice Direction, Appendix A, Part (a)(iii)).</p> <p>Previous Treatment: The OEB has previously recognized that estimated values that are the subject of ongoing negotiations should be subject to confidential treatment. (EB-2019-0018, Decision on Confidentiality, July 24, 2019, at p. 2) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit B1-1-1, Chart 2	Lines 4-8, 16-17	Yes	Confidential Treatment	<p>Commercially Sensitive Information: The redacted information consists of historical and forecasted inventory quantities and unit prices for uranium dioxide and finished fuel bundles, as well as forecasted inventory quantities and unit prices for uranium hexafluoride. Because OPG only has a single service provider for uranium dioxide conversion and a single service provider for CANDU fuel fabrication, these numbers in conjunction with the total inventory values could be used to calculate the service provider's contract unit pricing. Similarly, OPG only has two contracts for finished uranium hexafluoride (in respect of lines 16-17), so the information, if publicly disclosed, could be used by suppliers to</p>

² OPG submits that the information contained in these lines may be presumptively confidential. While these values include forecasted unit prices, the forecasts are based on actual unit prices which are presumptively confidential (Practice Direction, Appendix B, Part 1).

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>calculate commercially sensitive unit costs (Practice Direction, Appendix A, Part (a)(iii); Appendix B, Part 1).</p> <p>Previous Treatment: Third-party unit pricing is presumptively considered confidential under Part 1 of Appendix B of the Practice Direction, and the OEB has previously determined that information that can be used to calculate presumptively commercially sensitive information should be subject to confidential treatment. (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit C1-1-1, Attachment 2, Executed Engagement Letter for Concentric Energy Advisors	Pages 3-4	Yes	Confidential Treatment	<p>Billing Rates and Fees of Third Party: The information redacted consists of the billing rates for the service provided by a third-party consultant.</p> <p>Billing rate information is commercially sensitive. Public disclosure could prejudice the economic interest and competitive position of the vendor in any future negotiations for the provision of similar services (Practice Direction, Appendix B, Part 2).</p> <p>Previous Treatment: Information related to third party billing rates has been held confidential by the OEB previously due to its commercially sensitive nature and because it could prejudice that party's competitive position (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 5, 16; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit C1-1-1, Attachment 4, Executed Engagement Letter for Polar Star Advisory	Page 3 (section 5 only)	Yes	Confidential Treatment	<p>Billing Rates and Fees of Third Party: The information redacted consists of the billing rates for the service provided by a third-party consultant.</p> <p>Billing rate information is commercially sensitive. Public disclosure could prejudice the economic interest and competitive position of the vendor in</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>any future negotiations for the provision of similar services (Practice Direction, Appendix B, Part 2).</p> <p>Previous Treatment: Information related to third party billing rates has been held confidential by the OEB previously due to its commercially sensitive nature and because it could prejudice that party's competitive position (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 5, 16; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit C1-1-1, Attachment 4, Executed Engagement Letter for Polar Star Advisory	Pages 2-3 (section 4), 9	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: Polar Star Advisory has advised that these redacted terms from the Polar Star Engagement Letter are commercially sensitive, and if placed on the public record, could prejudice their competitive position and potentially produce a significant loss in future engagements. (Practice Direction, Appendix A, Part (a)).</p>
Exhibit C1-1-1, Attachment 4, Executed Engagement Letter for Polar Star Advisory	Page 6	No	Permanent Redaction for Non-Relevance; Confidential Treatment	<p>Non-relevant: These redacted portions of the Polar Star Engagement Letter include the personal contact information (home-office address and personal email) for Polar Star Advisory's ("Polar Star") President (the "Individual Information"). The Individual Information is not relevant to the determination of payment amounts under this proceeding (Practice Direction, Part 11).</p> <p>Public and Personal Security: OPG acknowledges that the Individual Information is not "Personal Information" as defined in the <i>Freedom of Information and Protection of Privacy Act</i>³ ("FIPPA") by virtue of its mixed personal and professional nature. However, the Individual Information is personally sensitive for the President of Polar Star and could present safety, security or other risks if disclosed on the public record. (Practice Direction, Appendix A, Part(c)).</p>

³ R.S.O. 1990, c. F.31, s. 2(4).

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: In EB-2023-0013 (Decision on Confidentiality), the OEB determined that home phone and personal cell phone numbers would qualify as “personal information” as defined in section 2(1) of FIPPA, but noted that even if the cell phone numbers were not for personal devices, that information would not be relevant to the proceeding. OPG submits that the Individual Information is analogous to the non-personal cell phone numbers referred to by the OEB in EB-2023-0013 and should be redacted from the public record for non-relevance (EB-2023-0013, Decision on Confidentiality, February 27, 2024, at p. 2) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit C1-1-2, Tables 4, 5, 6, 7	<p>Table 4, Lines 27 and 31</p> <p>Table 5, Lines 22-26</p> <p>Table 6, Lines 20-28</p> <p>Table 7, Lines 19-28</p>	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: Exhibit C1-1-2, Tables 4, 5, 6, and 7 include the confidential debt terms of OPG and the Canada Infrastructure Bank (“CIB”). CIB is a unique lender with a statutory mandate to invest in, and seek to attract investment in, infrastructure projects that will generate revenue and will be in the public interest. CIB debt terms are highly confidential as access to such information could give other parties information not otherwise available that could provide a commercial advantage unrelated to this proceeding in future dealings with CIB.</p> <p>To prevent the ability to calculate the redacted CIB terms with other information included in the Tables, ILB 5 values have also been redacted.</p> <p>Previous Treatment: This information was treated as confidential and subject to heightened confidentiality protections in EB-2024-0063 (Decision on Confidentiality, December 9, 2024), wherein the information was not required to be made available to certain utility participants even if a Declaration and Undertaking was filed. If this information is placed on the public record, in addition to the harms referenced above, the protections afforded in EB-2024-0063 would be nullified (EB-2024-0063, Decision on Confidentiality, December 9, 2024, at p. 4) (Practice Direction, Appendix A, Part (e)).</p> <p>Note that in order to preserve the confidentiality of the CIB debt terms, depending on the requests for intervenor status that are filed, OPG reserves the right to seek similar protections in this proceeding. OPG will</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				promptly advise the OEB of any such requests following the filing of requests for intervenor status.
Exhibit D1-1-2, Attachment 1, Tab 03, Sir Adam Beck I GS - G10 Major Overhaul & Upgrade	Page 2	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted provides indication of what course of action OPG may choose to pursue with a vendor.</p> <p>The redacted information is commercially sensitive, and it is kept confidential. It provides details of what OPG is willing and not willing to contest against a vendor in some unforeseen event. Public disclosure of this information could jeopardize future negotiations or claim disputes with this or other vendors. As a result, disclosure could significantly interfere with negotiations and prejudice OPG's competitive position (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>
Exhibit D1-1-2, Attachment 1, Tab 3, Sir Adam Beck I GS - G10 Major Overhaul & Upgrade	Pages 4, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of expected turbine efficiency gains, including the current and target result runner efficiency at its best efficiency point.</p> <p>The redacted information is commercially sensitive. Efficiency gains are kept confidential from competitors to OPG because this information would allow competitors to anticipate OPG's bidding behavior in the electricity market, plan strategies, and adjust their own market offers accordingly in a way that could harm competition in the IESO administered market. As a result, disclosure of efficiency gains could prejudice OPG's competitive position in the electricity market (Practice Direction, Appendix A, Part (a)(i)).</p> <p>Previous Treatment: The OEB has previously determined that information related to efficiency gains should be subject to confidential treatment (EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 5,	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Coniston/ Stinson GS Redevelopment				<p>or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 6, Calabogie GS - Redevelopment	Pages 2, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted relates to OPG complaining about vendor performance.</p> <p>The redacted information is commercially sensitive. Public disclosure of the redacted information could affect a vendor negatively because it concerns its performance. As a result, disclosure could damage the contractual relationship, prejudice the vendor and OPG's competitive position in the market, and jeopardize current or future negotiations. Disclosure could also result in reputational harm for that vendor (Practice Direction, Appendix A, Part (a)(i), (iii) and (iv)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to vendors' performance should be subject to confidential treatment because it could harm future negotiations, damage contractual relationships, prejudice the competitive position of the parties involved, and it could cause reputational harm to the vendors involved (see EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 15-17) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 7, G1 Capital Refurb	Pages 1, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D1-1-2, Attachment 1, Tab 8, Otter G1 Capital Upgrade	Pages 1, 8-9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5;) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 9,	Pages 1, 8-10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Otter G2 Capital Upgrade				<p>amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5;) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 9, Otter G2 Capital Upgrade	Pages 4, 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the names of technology providers –vendors OPG contracted for an ongoing project.</p> <p>The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendors' names that have been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG or increase their bids in negotiations with the vendors already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).
Exhibit D1-1-2, Attachment 1, Tab 9, Otter G2 Capital Upgrade	Page 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency amounts and OEB accepted that knowledge of contingency amounts</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5;) (Practice Direction, Appendix A, Part (e)).
Exhibit, D1-1-2, Attachment 1, Tab 10, Sir Adam Beck 1 GS - Unit G5 Upgrade	Page 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of expected turbine efficiency gains, including the current and target result runner efficiency at its best efficiency point.</p> <p>The redacted information is commercially sensitive. Efficiency gains are kept confidential from competitors to OPG because this information would allow competitors to anticipate OPG's bidding behavior in the electricity market, plan strategies, and adjust their own market offers accordingly in a way that could harm competition in the IESO administered market. As a result, disclosure of efficiency gains could prejudice OPG's competitive position in the electricity market (Practice Direction, Appendix A, Part (a)(i)).</p> <p>Previous Treatment: The OEB has previously determined that information related to efficiency gains should be subject to confidential treatment (EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 11, ABI - G1 Capital Upgrades	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 14, Frederick House Lake Dam Upgrades	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5;) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 15, SAU - G9 Capital Refurbishment	Pages 1, 7-8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D1-1-2, Attachment 1, Tab 16, Surge Tank Replacement	Pages 1, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 17, SAB G1/G2 Replacement	Page 3	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted relates to historical river flow information.</p> <p>The redacted information is commercially sensitive, and it is kept confidential. Public disclosure of historical river flow information can be exploited to model one of OPG's renewable generation complexes and</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				create a price forecast. As a result, disclosure could prejudice OPG's competitive position leading to economic harm (Practice Direction, Appendix A, Part (a)(i)).
Exhibit D1-1-2, Attachment 1, Tab 19, CHE - Limerick Isl. Spr Structure Sluice Gate Hoist	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 20,	Pages 1, 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
NWO Work Centre Building				<p>or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 21, Otter Project Camp	Pages 1, 6-7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 22, SAB1 Station Service Upgrade	Pages 1, 5-6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, dated March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 23, BK1 G6 G8 Refurbishment	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D1-1-2, Attachment 1, Tab 24, Kakabeka Falls GS	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D1-1-2, Attachment 1, Tab 25, Matabitchuan GS	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 26, BK1 G4 Refurbishment	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 26, BK1 G4 Refurbishment	Page 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of expected turbine efficiency gains, including the current and target result runner efficiency at its best efficiency point.</p> <p>The redacted information is commercially sensitive. Efficiency gains are kept confidential from competitors to OPG because this information would allow competitors to anticipate OPG's bidding behavior in the electricity market, plan strategies, and adjust their own market offers accordingly in a way that could harm competition in the IESO administered market. As a result, disclosure of efficiency gains could prejudice OPG's competitive position in the electricity market (Practice Direction, Appendix A, Part (a)(i)).</p> <p>Previous Treatment: The OEB has previously determined that information related to efficiency gains should be subject to confidential</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				treatment (EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 5) (Practice Direction, Appendix A, Part (e)).
Exhibit, D1-1-2, Attachment 1, Tab 27, SAU - G12 Capital Refurbishment	Pages 1, 7, 9-10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit, D1-1-2, Attachment 1, Tab 28, SAU – Long Sault	Pages 1, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Dam Capital Program (JW)(NYPA)				<p>or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit, D1-1-2, Attachment 1, Tab 29, G2 Capital Refurb	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 30, G3 Capital Refurb	Pages 1, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 31, MAN G3 Capital Refurb	Pages 1, 7-8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D1-1-2, Attachment 1, Tab 32, SAU - G16 Capital Refurbishment	Pages 1, 6-7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D1-1-2, Attachment 1, Tab 33, SAU - Massena Canal Dam (JW)(NYPA)(CAP)	Pages 1, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 34, Timmins Building Expansion	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 35, Aguasabon Dam Rehab. Hayes Lake Main Dam	Pages 1, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 36, Dymond Shop Machine Expansion	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D1-1-2, Attachment 1, Tab 36, Dymond Shop Machine Expansion	Page 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the name of a technology provider – a vendor OPG contracted for an ongoing project.</p> <p>The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendor’s name that has been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG or increase their bids in negotiations with a vendor already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG’s competitive position to the detriment of OPG’s cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>
Exhibit, D1-1-2, Attachment 1, Tab 37, BK2 G18 G17 Refurbishment	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 38, BK2 G14 G13 Refurbishment	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 39, BK2 230kV Conductor Replacement	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D1-1-2, Attachment 1, Tab 40, SAU - Long Sault Dam Downstream Concrete JW NYP	Pages 1-2, 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D1-1-2, Attachment 1, Tab 41, BK2 G20/G19 Refurbishment	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 42, SAB1 Canal Isolation Preparedness Phase 1 (SAB1 CIP1)	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D1-1-2, Attachment 1, Tab 43, OTO - Refurbish Stop Log Sluice Piers	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit, D1-1-2, Attachment 1, Tab 44, Abitibi Canyon Concrete Repair Zone 7	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 1, DN Class II Uninterruptable Power Supply Replacement	Pages 1, 7-8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, and interest) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 1, DN Class II Uninterruptable Power Supply Replacement	Page 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency amounts and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 2,	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
DN Station Roofs Replacement				<p>or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 3, DN Powerhouse Water Air Condition Units Replacement	Pages 1, 10-11	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., design contract, construction contract, EPC contract, consultants, other contract costs, interest, and subtotal) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 3, DN Powerhouse Water Air Condition Units Replacement	Page 11	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency amounts and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 3, DN Powerhouse Water Air Condition Units Replacement	Pages 2, 5, 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the Estimate at Completion dollar value for an ongoing project. Unlike total project costs, Estimate at Completion represents an internal forecast of how total project costs progress and trend at a specific point-in-time, and as such it will change over the life of a project. Estimate at Completion could be used to determine project's contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. The Estimate at Completion value is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the Estimate at Completion dollar value will enable vendors to determine the contingency amounts for the project and vendors could increase their bids to maximize profits, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB’s previous decisions insofar as disclosing Estimate at Completion value will reveal the contingency amount for the project and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 4, DN Water Treatment Plant Interconnections	Pages 1, 6-7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG’s competitive position to the detriment of OPG’s cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 5, DN Radiation Detection Equipment Obsolescence	Pages 1-3, 5, 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., cost management, project management, inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, other, and removal costs) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 5, DN Radiation Detection Equipment Obsolescence	Page 2	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency amounts and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 6, DN Air Conditioning	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Unit Replacement For Secondary Control Area				<p>or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 7, DN Major Pump-Sets Vibration Monitoring System Upgrades	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 7, DN Major Pump-Sets Vibration Monitoring System Upgrades	Page 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency amounts and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 8, DN Standby Generator Controls Replacement	Pages 1-2, 12-14	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., design and construction contracts, EPC contracts, consultants, other contract costs, other, interest, and subtotal) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 8, DN Standby Generator Controls Replacement	Pages 13-14	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) and related comments for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				amounts and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 8, DN Standby Generator Controls Replacement	Pages 2, 5, 12	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the Estimate at Completion dollar value for an ongoing project. Unlike total project costs, Estimate at Completion represents an internal forecast of how total project costs progress and trend at a specific point-in-time, and as such it will change over the life of a project. Estimate at Completion could be used to determine project's contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. The Estimate at Completion value is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the Estimate at Completion dollar value will enable vendors to determine the contingency amounts for the project and vendors could increase their bids to maximize profits, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing Estimate at Completion value will reveal the contingency amount for the project and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 9, DN OH180 Aging Management Hardware Installation	Pages 1, 3, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, cost management, closeout, subtotal, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 10, DN R22 Refrigerant	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Air Conditioning Unit Replacement				<p>amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 11, DN Digital Control, Common Process And Sequence Of Events Monitoring Computer Aging Management	Pages 1, 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 12, DN Main Power Output Protection System Replacement	Pages 1, 10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 13, DN Group II Pressure Transmitter Replacement	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 13, DN Group II Pressure Transmitter Replacement	Page 2	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the name of a technology provider – a vendor OPG contracted for an ongoing project.</p> <p>The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendor’s name that has been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG or increase their bids in negotiations with a vendor already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG’s competitive position to the detriment of OPG’s cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>
Exhibit D2-1-3, Attachment 1, Tab 14, DN Obsolete Controller Replacement	Pages 1, 11	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., OPG engineering, OPG procured materials, OPG execution, closeout, interest, and subtotal) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 14, DN Obsolete Controller Replacement	Pages 3-4, 6, 11	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the Estimate at Completion dollar value for an ongoing project. Unlike total project costs, Estimate at Completion represents an internal forecast of how total project costs progress and trend at a specific point-in-time, and as such it will change over the life of a project. Estimate at Completion could be used to determine project's contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. The Estimate at Completion value is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the Estimate at Completion dollar value will enable vendors to determine the contingency amounts for the project and vendors could increase their bids to maximize profits, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing Estimate at Completion value will reveal the contingency amount for the project and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 15, DN Emergency Power Generator 1 And 2 Replacement	Pages 1, 6-7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering contracts, construction contract – procurement, construction contract – construction, other contracts, subtotal, and interest) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 15, DN Emergency Power Generator 1 And 2 Replacement	Page 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific variance amounts (variance breakdown) for an ongoing project. Variance amounts represent the difference between budgeted and actual costs that may arise as a result of changes to base assumptions. Confidential treatment is not being sought for the total variance amount or total project costs.</p> <p>The redacted information is commercially sensitive. The breakdown of specific variance amounts, which shows project costs including contingency allotted for new releases of funds, is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the variance breakdown will provide the vendors involved in a project with visibility into specific variance amounts and the additional contingency associated with changes to baseline assumptions. This can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding including contingency. As a result, disclosure could significantly interfere with current or future negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing the variance breakdown will reveal contingency amounts and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 16, DN Fuel Handling Computer Input/ Output Subsystem Interprocessor Communication Replacement	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 17, DN Fire Resistant Fluid Pump Improvement	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, and interest) have been redacted as well insofar as these can be used to determine the</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 18, DN Fuel Handling Head Major Component Replacement	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 19, DN Rapid Delivery Machine	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 20, DN Main Output Transformer & Unit Service Transformer Replacement	Pages 1, 12-14	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., OPG procured materials, EPC contracts, interest, and subtotal) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 20, DN Main Output Transformer & Unit Service Transformer Replacement	Pages 3, 6, 12	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the Estimate at Completion dollar value for an ongoing project. Unlike total project costs, Estimate at Completion represents an internal forecast of how total project costs progress and trend at a specific point-in-time, and as such it will change over the life of a project. Estimate at Completion could be used to determine project's contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. The Estimate at Completion value is kept confidential from vendors as a means for OPG to control project costs. Public disclosure of the Estimate at Completion dollar value will enable vendors to determine the contingency amounts for the project and vendors could increase their bids to maximize profits, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. Reference is made to OEB's previous decisions insofar as disclosing Estimate at Completion value will reveal the contingency amount for the project and OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 20, DN Main Output Transformer & Unit	Page 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the name of a technology provider – a vendor OPG contracted for an ongoing project.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Service Transformer Replacement				The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendor's name that has been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG or increase their bids in negotiations with a vendor already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).
Exhibit D2-1-3, Attachment 1, Tab 21, DN Large Moderator Temperature Control Valve Replacement	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 22, DN Secondary System Obsolete Control Valve Replacement	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 23, DN 4KV Motor Refurbishment And Replacement	Pages 1, 12	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., project management, inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 24,	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
DN Isolated Phase Bus Refurbishment				<p>amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, and interest) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 25, DN Powerhouse Upper Level Service Water Piping Replacement	Pages 1, 9-10	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 26, DN Unit 2 Turbine Control System Upgrade	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 26, DN Unit 2 Turbine Control System Upgrade	Page 4	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the name of a technology provider – a vendor OPG contracted for an ongoing project.</p> <p>The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendor’s name that has been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG or increase their bids in negotiations with a vendor already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG’s competitive position to the detriment of OPG’s cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>
Exhibit D2-1-3, Attachment 1, Tab 27, DN Primary Heat Transport Liquid Relief Valve Modifications (Waterhammer)	Pages 1, 7	No	Confidential Treatment	Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, execution, closeout, subtotal, interest, and other) have been redacted as well insofar as these

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 28, DN Motor Operated Valve Replacements	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 29, DN Revenue Metering Transformer Replacement	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 34, DN Steam Generator Level Control Valve Replacement	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 34, DN Steam Generator Level Control Valve Replacement	Pages 2-4	No	Confidential Treatment	<p>Commercially Sensitive Information The information redacted consists of the name of a technology provider, and the equipment OPG decided to purchase from that vendor by reference to the equipment make and model, which can be used to determine the vendor itself (Original Equipment Manufacturer). It also includes a reference to unsatisfactory performance of the equipment.</p> <p>The redacted information is commercially sensitive. Public disclosure of the redacted information could affect a vendor negatively because it concerns an OPG complaint about vendor's unsatisfactory performance. As a result, disclosure could damage the contractual relationship, prejudice the vendor and OPG's competitive position in the market, and jeopardize current or future negotiations. Disclosure could also result in reputational harm for that vendor (Practice Direction, Appendix A, Part (a)(i), (iii) and (iv)).</p> <p>Previous Treatment: The OEB has previously determined that information related to vendors' performance should be subject to confidential treatment because it could harm future negotiations, damage contractual relationships, prejudice the competitive position of the parties involved, and it could cause reputational harm to the vendors involved (see EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 15-17) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 36, DN Public Address System Upgrade	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 37, DN Breathing, Instrument and Service Air Compressor Replacement	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 38, DN Powerhouse Elevator Replacement	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, and interest) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 39, DN Powerhouse Cranes Refurbishment	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 40, DN Vacuum Building Outage Power	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Operated Valves Replacement				<p>project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 41, Tritium Removal Facility Major Component Replacement Program	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 42, DN Low Pressure Service Water Strainer Backwash Motorized Valves Replacement	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., project management, inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 43, Darlington Steam Generator Moisture Separator Replacement	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., procurement, construction, commissioning, closeout, subtotal, outside WBS, and interest) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 44, DN Motor Operated Valve Replacement Innage	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 45, DN Lighting	Pages 1, 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Fixtures Light Emitting Diode Replacement				<p>project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 46, DN Copper Upgrades Phase III.	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 47, DN Unit 2 and 3 Steam Generator Moisture Separator Replacement	Pages 1, 8	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., project management, inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 47, DN Unit 2 and 3 Steam Generator Moisture Separator Replacement	Pages 5-6	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the name of a technology provider – a vendor OPG contracted for an ongoing project.</p> <p>The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendor's name that has been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG or increase their bids in negotiations with a vendor already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p>
Exhibit D2-1-3, Attachment 1, Tab 48, DN Tritium Removal Facility Cryogenic Refrigeration System Turbine Replacement	Pages 1, 7	No	Confidential Treatment	Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 48, DN Tritium Removal Facility Cryogenic Refrigeration System Turbine Replacement	Page 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of the name of a technology provider – a vendor OPG contracted for an ongoing project.</p> <p>The redacted information is commercially sensitive. It is kept confidential from competing vendors as a means for OPG to protect information about strategic sourcing decisions, proprietary technological choices, negotiations with vendors, and to control project costs. Public disclosure of vendor's name that has been contracted or negotiated with for a particular project or type of work could be exploited by competing vendors as they will be guided to search for other available information about vendor equipment, models, and prices, and therefore build a credible project vendor cost profile. Combined with the information about total project costs and scope of work, competing vendors could increase their bids to maximize profits in current or future negotiations with OPG</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				or increase their bids in negotiations with a vendor already selected by OPG. As a result, disclosure could significantly interfere with negotiations and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts (Practice Direction, Appendix A, Part (a)(i) and (iii)).
Exhibit D2-1-3, Attachment 1, Tab 49, DN Turbine Rotors Replacements & Capital Spare	Pages 1, 10-11	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 50, DN Smartops Sensor Integration	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., project management, inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 51, DN Unit 1 and 2 Generator Stator Rewind	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 52, DN Steam Generator Soft Chemical Clean	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-1-3, Attachment 1, Tab 53, PN 058 Boiler Room and Turbine Hall Crane Upgrade	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D2-1-3, Attachment 1, Tab 54, PN 058 Turbine Auxiliary Building, Reactor Auxiliary Building Hoist & Cranes	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-1-3, Attachment 1, Tab 55, P58 Second Simulator and Pickering Learning Centre Extension	Pages 1, 5	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-3-3, Attachment 1, Contract Summary for RFBR with Atkins/Aecon JV	Pages 3-4	No	Confidential Treatment	<p>Commercially Sensitive Information: The redacted information relates to rework percentage amounts, neutral band borders, and incentive/disincentive caps. Rework percentage amounts reflect performance thresholds and risk tolerances.</p> <p>The redacted information is commercially sensitive. Public disclosure of these percentages could enable vendors or contractors to tailor their</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>proposals or performance to meet the amounts set out in this contract summary, reducing competitive pressure. Neutral bands define the range within which no incentive or disincentive is paid. The disclosure of these borders could allow counterparties to optimize their bids or project execution strategies to fall within the band, undermining the effectiveness of performance-based mechanisms. Incentive and disincentive caps set limits on financial exposures related to performance. If disclosed, contractors or vendors may adjust their pricing, risk-sharing, or negotiation strategies to maximize their benefit or minimize their exposure, eroding competitiveness and potentially increasing costs. Additionally, public knowledge of these bands, caps, and percentages could set informal benchmarks in the market, undermining the ability of OPG to negotiate the best possible terms in future contracts.</p> <p>As a result, publicly available details of these commercial percentages and figures could prejudice OPG's negotiating position in current or future procurements, eroding OPG's competitiveness and potentially increasing costs (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that revealing specific numbers relating to risks, rewards, and continuous improvements could be detrimental to commercial interests, and as such, should be subject to confidential treatment (EB-2016-0152, Decision and Order on Confidentiality, January 31, 2017, at pp. 4-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit, D2-3-3, Attachment 2, Contract Summary for Turbine Generators with the TG Consortium	Pages 5- 6	No	Confidential Treatment	<p>Commercially Sensitive Information: The redacted information relates to neutral band borders, and incentive/disincentive caps. Neutral bands define the range within which no incentive or disincentive is paid.</p> <p>The redacted information is commercially sensitive. Public disclosure of these borders could allow counterparties to optimize their bids or project execution strategies to fall within the band, undermining the effectiveness of performance-based mechanisms. Incentive and disincentive caps set limits on financial exposures related to performance. If disclosed, contractors or vendors may adjust their pricing, risk-sharing, or negotiation strategies to maximize their benefit</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>or minimize their exposure, eroding competitiveness and potentially increasing costs. Additionally, public knowledge of these bands and caps could set informal benchmarks in the market, undermining the ability of OPG to negotiate the best possible terms in future contracts.</p> <p>As a result, publicly available details of these commercial percentages and figures could prejudice OPG's negotiating position in current or future procurements, eroding OPG's competitiveness and potentially increasing costs (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that revealing specific numbers relating to risks, rewards, and continuous improvements could be detrimental to commercial interests, and as such, should be subject to confidential treatment (EB-2016-0152, Decision and Order on Confidentiality, January 31, 2017, at pp. 4-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-3-3, Attachment 3, Contract Summary for DWI	Pages 4-5, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The redacted information relates to neutral band borders, incentive/disincentive caps, and performance security values. Neutral bands define the range within which no incentive or disincentive is paid.</p> <p>The redacted information is commercially sensitive. Public disclosure of these borders could allow counterparties to optimize their bids or project execution strategies to fall within the band, undermining the effectiveness of performance-based mechanisms. Incentive and disincentive caps set limits on financial exposures related to performance. If disclosed, contractors or vendors may adjust their pricing, risk-sharing, or negotiation strategies to maximize their benefit or minimize their exposure, eroding competitiveness and potentially increasing costs. Additionally, public knowledge of these bands, caps, and security value could set informal benchmarks in the market, undermining the ability of OPG to negotiate the best possible terms in future contracts.</p> <p>As a result, publicly available details of these commercial percentages and figures could prejudice OPG's negotiating position in current or</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>future procurements, eroding OPG's competitiveness and potentially increasing costs (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>In addition, this contract was awarded via a competitive procurement process. Disclosing such commercial information could result in future proponents in similar procurements tailoring their bids to meet or exploit disclosed thresholds, band, or security requirements, reducing OPG's competitiveness and potentially increasing costs for ratepayers (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that revealing specific numbers relating to risks, rewards, and continuous improvements could be detrimental to commercial interests, and as such, should be subject to confidential treatment (EB-2016-0152, Decision and Order on Confidentiality, January 31, 2017, at pp. 4-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-3-3, Attachment 4, ESMSA Contract Summary and ESMSA Worksheet Template	Pages 5-7	No	Confidential Treatment	<p>Commercially Sensitive Information: The redacted information relates to neutral band borders, incentive/disincentive caps, administration fees for contractors and subcontractors, and performance security values. Neutral bands define the range within which no incentive or disincentive is paid.</p> <p>The redacted information is commercially sensitive. Public disclosure of these borders could allow counterparties to optimize their bids or project execution strategies to fall within the band, undermining the effectiveness of performance-based mechanisms. Incentive and disincentive caps set limits on financial exposures related to performance. If disclosed, contractors or vendors may adjust their pricing, risk-sharing, or negotiation strategies to maximize their benefit or minimize their exposure, eroding OPG's competitiveness and potentially increasing costs.</p> <p>Administration fees are amounts billed by a contractor or subcontractor to cover costs associated with managing, coordinating, and administering work or services under a contract. Administration fees are commercial terms negotiated between parties. Disclosure of these rates may tailor the proposals of future bidders to match or undercut these</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>fees, reducing competitive tension and potentially leading to higher costs.</p> <p>Additionally, public knowledge of these bands, caps, fees, and security values could set informal benchmarks in the market, undermining the ability of OPG to negotiate the best possible terms in future contracts.</p> <p>As a result, publicly available details of these commercial percentages and figures could prejudice OPG's negotiating position in current or future procurements, eroding competitiveness and potentially increasing costs (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>In addition, this contract was awarded via a competitive procurement process. Disclosing such commercial information could result in future proponents in similar procurements tailoring their bids to meet or exploit disclosed thresholds, band, or security requirements, reducing OPG's competitiveness, and potentially increasing costs (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that revealing specific numbers relating to risks, rewards, and continuous improvements could be detrimental to commercial interests, and as such, should be subject to confidential treatment (EB-2016-0152, Decision and Order on Confidentiality, January 31, 2017, at pp. 4-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D3-1-2, Attachment 1, Tab 2, DNNP Enterprise Asset Management	Pages 1, 7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., engineering, procurement, construction, commissioning, closeout, subtotal, and interest) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D3-1-2, Attachment 1, Tab 3, Integrated HR Service Delivery	Pages 1, 8-9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).
Exhibit D3-1-2, Attachment 1, Tab 4, Finance ERP Solution	Pages 1, 6-7	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for a new project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG's competitive position to the detriment of OPG's cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit D2-4-3, Attachment 2, Integrated Project Agreement Summary	All	No	Confidential Treatment	<p>Commercially Sensitive Information and Competitive Prejudice: Exhibit D2-4-3, Attachment 2 is a detailed summary of the DNNP Integrated Project Agreement (“IPA”). If this summary were disclosed, it would harm OPG’s competitive position for the reasons outlined below (Practice Direction, Appendix A, Part a(i)).</p> <p>The IPA is a novel, highly sensitive commercial agreement. Darlington New Nuclear Project (“DNNP”) will be the first nuclear project to deploy an Integrated Project Delivery (“IPD”) model, and the IPA provides the contractual roadmap for adapting this delivery model to Small Modular Reactor (“SMR”) technology. The IPA therefore places OPG in the lead to build the first SMR in North America, but many global competitors are trying to catch up. At least five other companies in North America and Europe have announced plans to develop an SMR.</p> <p>The IPA summary at Exhibit D2-4-3, Attachment 2 reveals commercially sensitive details about the IPA that OPG’s competitors do not have, including the key terms and structure of the IPA, the specific commitments the parties undertook, and how the IPA operationalizes the IPD model in the SMR context.</p> <p>OPG recognizes the importance of providing information to the public about the IPA and DNNP. That is why in its evidence filed in this Exhibit D2-4-3, OPG has provided an overview of the IPA and described some of its commercial terms and contracting approaches. But in light of OPG’s public disclosures to date, any incremental benefits of further disclosure do not outweigh the competitive harms from disclosing granular details about the IPA in the summary.</p> <p>In addition, one of the OEB’s statutory objectives is to “facilitate innovation in the electricity sector,”⁴ and the IPA represents a first-of-a-kind approach to nuclear power generation. Relying on its mandate to promote innovation, the OEB recently protected evidence that “reflects proprietary frameworks, methodologies and analytical models developed through investment in intellectual capital, industry experience and</p>

⁴ Ontario.Energy.Board.Act, 1998, S.O. 1998, c. 15, Sched. B, s.1(1)(4).

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>innovation” (EB-2024-0115, Decision on Confidentiality, November 3, 2025, at p. 4). OPG’s form of contracting and project implementation described in the IPA summary reflect proprietary and novel approaches as well and should also be protected.</p> <p>Impact on Future Negotiations: During the execution of Unit 1, OPG will continue planning and preparing for the remaining three units at the DNNP site. During this time, OPG will continue to negotiate agreements for the construction and development of those three units, potentially with new counterparties.</p> <p>Disclosing the IPA summary will harm OPG’s position in those negotiations (Practice Direction, Appendix A, Part (a)(i)). If disclosed, the IPA’s key terms and other contracting features will act as a baseline in future negotiations, impairing OPG’s flexibility when negotiating future SMR execution agreements. If the IPA summary is made public, any compromises that OPG’s counterparties made in the IPA will also become public. This would impair OPG’s relationship with those parties and impair their future negotiating position on other projects.</p> <p>Subject to Privacy Commissioner Appeal: The IPA is also subject to an ongoing appeal before Ontario’s Information and Privacy Commissioner (“IPC”). Relying on several exemptions to FIPPA, OPG has denied access to a request for disclosure of the IPA. OPG has maintained confidentiality over the IPA itself and summaries and descriptions of the IPA filed with the IPC.</p> <p>Given the pending IPC appeal, the OEB should maintain confidentiality of the IPA summary. Otherwise, public disclosure of the IPA summary in this application would pre-empt the IPC’s consideration of the appeal, rendering it largely moot.</p>
Exhibit D2-4-8, Attachment 1, DNNP Unit 1 Execution Phase Funding Release and Units 2-4 Definition Phase	Pages 1-2, 4-5 Appendices 1, 3-4, 6-7, 8, 10	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: The information includes detailed financial and scheduling information relating to units 2, 3 and 4 (the “Future Units”) of the Darlington New Nuclear Project (“DNNP”), including, in respect of the Future Units, financial contingencies, expected interest and escalation, levelized cost of electricity (“LCOE”), and granular scheduling information (beyond the projected DNNP completion year of 2035). OPG</p>

Appendix A

Exhibit Reference	Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Funding Release, March 2025			<p>is not seeking to redact total DNNP project costs, the portion of the total DNNP project costs attributable to the Future Units, or the planned year of completion relating to the DNNP. Because none of the Future Units will enter commercial operation or have any associated forecast in-service amounts entering rate base during the future rate period, the detailed information pertaining to the Future Units is beyond the scope of issues that will be decided as part of this proceeding, and accordingly, it will not provide any assistance to the Board or intervenors (Practice Direction, Part 11).</p> <p>Competitive Prejudice: The financial information is commercially sensitive, notably the detailed estimates of various cost components included in Appendix 1 and Appendix 7 to the DNNP RQE. It is sensitive because this granular costing breakdown of DNNP is unknown and highly desirable by OPG's competitors. If revealed, OPG's competitive position as a global leader in SMR technology would be prejudiced because competitors could use these figures, which are based on OPG's extensive research and development, to reverse-engineer the costing of DNNP to assist in the development their own competing projects (Practice Direction, Appendix A, Part (a) (i),(iii),(iv)). Noting that one of the OEB's statutory objectives is to "facilitate innovation in the electricity sector," OPG asserts that this objective will be best served by protecting OPG's sensitive financial information underlying the DNNP, which represents first-of-a-kind approach to nuclear power generation.</p> <p>Impact on Future Negotiations: OPG has not yet entered into agreements for the construction and development of the Future Units. Disclosing the detailed financial information relating to the Future Units will harm OPG's position in those negotiations. Disclosing this information will provide OPG's counterparties with a basis to estimate cost projections for specific portions of the project, which can compromise the vendor bids and OPG's ability to negotiate competitive pricing for the service in question (Practice Direction, Appendix A, Part (a)(iii)). To this end, this information could send a signal to proponents in future procurement that OPG is willing to accept the estimated prices in question, which will incentivize them to submit bids that are no lower than the prices, at the expense of ratepayers.</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: In EB-2010-0008, OPG sought to redact the LCOE (called LUEC at the time) related to the Darlington Refurbishment Project. The OEB agreed to redact these figures (EB-2010-0008, Decision and Orders on Confidential Filings and Issues List, and Procedural Order No. 3., EB-2010-0008, July 21, 2010, at pp. 3-4) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit D2-4-10, Attachment 2, Pegasus Global Holdings, Inc. Engagement Letter	Page 3	Yes	Confidential Treatment	<p>Billing Rates and Fees of Third Party: The information redacted consists of the billing rates for the service provided by a third-party consultant.</p> <p>Billing rate information is commercially sensitive. Public disclosure could prejudice the economic interest and competitive position of the vendor in any future negotiations for the provision of similar services (Practice Direction, Appendix B, Part 2).</p> <p>Previous Treatment: Information related to third party billing rates has been held confidential by the OEB previously due to its commercially sensitive nature and because it could prejudice that party's competitive position (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 5, 16; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit F2-1-1, Attachment 6, ScottMadden Evaluation of OPG Nuclear Benchmarking Retainer Letter	Page 2	Yes	Confidential Treatment	<p>Billing Rates and Fees of Third Party: The information redacted consists of the billing rates for the service provided by a third-party consultant.</p> <p>Billing rate information is commercially sensitive. Public disclosure could prejudice the economic interest and competitive position of the vendor in any future negotiations for the provision of similar services (Practice Direction, Appendix B, Part 2).</p> <p>Previous Treatment: Information related to third party billing rates has been held confidential by the OEB previously due to its commercially sensitive nature and because it could prejudice that party's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				position (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 5, 16; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).
Exhibit F2-1-1, Attachment 7, ScottMadden OPG Nuclear Cost Performance Benchmarking Retainer Letter	Page 2	Yes	Confidential Treatment	<p>Billing Rates and Fees of Third Party: The information redacted consists of the billing rates for the service provided by a third-party consultant.</p> <p>Billing rate information is commercially sensitive. Public disclosure could prejudice the economic interest and competitive position of the vendor in any future negotiations for the provision of similar services (Practice Direction, Appendix B, Part 2).</p> <p>Previous Treatment: Information related to third party billing rates has been held confidential by the OEB previously due to its commercially sensitive nature and because it could prejudice that party's competitive position (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 5, 16; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit F2-1-1, Attachment 8, Indeavor Nuclear Staffing Benchmarking Analysis Retainer Letter	Page 2	Yes	Confidential Treatment	<p>Billing Rates and Fees of Third Party: The information redacted consists of the billing rates for the service provided by a third-party consultant.</p> <p>Billing rate information is commercially sensitive. Public disclosure could prejudice the economic interest and competitive position of the vendor in any future negotiations for the provision of similar services (Practice Direction, Appendix B, Part 2).</p> <p>Previous Treatment: Information related to third party billing rates has been held confidential by the OEB previously due to its commercially sensitive nature and because it could prejudice that party's competitive</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				position (EB-2020-0290, Decision on Confidentiality – Pre-Filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at pp. 5, 16; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3) (Practice Direction, Appendix A, Part (e)).
Exhibit F2-3-3, Attachment 1, Tab 1, Darlington U0 Switchgear Refurbishment	Pages 1, 9	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of specific contingency amounts for an ongoing project. Contingency amounts represent an allowance for discrete project risks or issues that may arise throughout the course of a project. Other amounts related to project costs (e.g., project management, inspection, engineering, procurement, construction, commissioning, closeout, subtotal, outside WBS, interest, and other) have been redacted as well insofar as these can be used to determine the contingency amounts. Confidential treatment is not being sought for the total project costs.</p> <p>The redacted information is commercially sensitive. Contingency amounts are kept confidential from vendors as a means for OPG to control project costs. Public disclosure of contingency amounts can result in vendors increasing their bids to maximize profit, based on the knowledge that OPG has budgeted additional funding to pay for contingency. As a result, disclosure could significantly interfere with negotiations, or claim disputes, and prejudice OPG’s competitive position to the detriment of OPG’s cost efficiency efforts and ultimately the contract price (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information related to contingency amounts and other information that could be used to determine contingency amounts should be subject to confidential treatment. The OEB accepted that knowledge of contingency amounts could affect negotiations and contract price (EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 5; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at pp. 3-5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit F4-2-1, Table 4	Columns a)-d)	Yes	Confidential Treatment	<p>Confidential, Non-public Financial Information of an Unregulated Affiliate Engaged in Competitive Business Activity: The redacted portions of Exhibit F4-2-1, Table 4 should be protected as confidential because it includes a significant amount of information that relates to the unregulated aspects of OPG’s business, both at the OPG corporate level and with respect to unregulated entities. This information is not relevant to this Application and OPG consistently treats it as confidential financial information (Practice Direction, Appendix A, Part (b); Appendix B, Part 5).</p> <p>Previous Treatment: The OEB has previously found this type of tax information to be confidential. The confidential nature of this information was approved by the OEB in previous OPG proceedings (EB-2020-0290, Procedural Order No. 1, February 17, 2021, at p. 5; EB-2016-0152, Procedural Order No. 1, August 16, 2016, at p. 6; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p.3; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p.4) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit F4-2-1, Attachment 1, Part 1, T2 Corporation Income Tax Return Ontario Power Generation Inc.	All	Yes	Confidential Treatment	<p>Confidential, Non-public Financial Information of an Unregulated Affiliate Engaged in Competitive Business Activity: The 2024 Income Tax Return for Ontario Power Generation Inc. located at Exhibit F4-2-1, Attachment 1, Part 1 should be protected as confidential because it includes a significant amount of information that relates to the unregulated aspects of OPG’s business, both at the OPG corporate level and with respect to unregulated entities. This information is not relevant to this Application and OPG consistently treats it as confidential financial information (Practice Direction, Appendix A, Part (b); Appendix B, Part 5).</p> <p>Previous Treatment: The OEB has previously found this type of tax information to be confidential. The confidential nature of this information was approved by the OEB in previous OPG proceedings (EB-2020-0290, Procedural Order No. 1, February 17, 2021, at p. 5; EB-2016-0152, Procedural Order No. 1, August 16, 2016, at p. 6; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p.3; EB-2010-0008,</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Procedural Order No. 3, July 21, 2010, at p.4) (Practice Direction, Appendix A, Part (e)).
Exhibit F4-2-1, Attachment 1, Part 2, T2 Corporation Income Tax Return OPG – Huron A Inc.	All	Yes	Confidential Treatment	<p>Confidential, Non-public Financial Information of an Unregulated Affiliate Engaged in Competitive Business Activity: The 2024 Income Tax Return for OPG – Huron A Inc. located at Exhibit F4-2-1, Attachment 1, Part 2 should be protected as confidential because it includes a significant amount of information that relates to the unregulated aspects of OPG's business, both at the OPG corporate level and with respect to unregulated entities. This information is not relevant to this Application and OPG consistently treats it as confidential financial information (Practice Direction, Appendix A, Part (b); Appendix B, Part 5).</p> <p>Previous Treatment: The OEB has previously found this type of tax information to be confidential. The confidential nature of this information was approved by the OEB in previous OPG proceedings (EB-2020-0290, Procedural Order No. 1, February 17, 2021, at p. 5; EB-2016-0152, Procedural Order No. 1, August 16, 2016, at p. 6; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p.3; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p.4) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit F4-2-1, Attachment 1, Part 3, T2 Corporation Income Tax Return OPG – Huron B Inc.	All	Yes	Confidential Treatment	<p>Confidential, Non-public Financial Information of an Unregulated Affiliate Engaged in Competitive Business Activity. The 2024 Income Tax Return for OPG – Huron B Inc. located at Exhibit F4-2-1, Attachment 1, Part 3 should be protected as confidential because it includes a significant amount of information that relates to the unregulated aspects of OPG's business, both at the OPG corporate level and with respect to unregulated entities. This information is not relevant to this Application and OPG consistently treats it as confidential financial information (Practice Direction, Appendix A, Part (b); Appendix B, Part 5).</p> <p>Previous Treatment: The OEB has previously found this type of tax information to be confidential. The confidential nature of this information was approved by the OEB in previous OPG proceedings (EB-2020-0290, Procedural Order No. 1, February 17, 2021, at p. 5; EB-2016-0152,</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				Procedural Order No. 1, August 16, 2016, at p. 6; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p.3; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p.4) (Practice Direction, Appendix A, Part (e)).
Exhibit F4-2-1, Attachment 1, Part 4, T2 Corporation Income Tax Return OPG – Huron Common Facilities Inc.	All	Yes	Confidential Treatment	<p>Confidential, Non-public Financial Information of an Unregulated Affiliate Engaged in Competitive Business Activity. The 2024 Income Tax Return for OPG – Huron Common Facilities Inc. located at Exhibit F4-2-1, Attachment 1, Part 4 should be protected as confidential because it includes a significant amount of information that relates to the unregulated aspects of OPG’s business, both at the OPG corporate level and with respect to unregulated entities. This information is not relevant to this Application and OPG consistently treats it as confidential financial information (Practice Direction, Appendix A, Part (b); Appendix B, Part 5).</p> <p>Previous Treatment: The OEB has previously found this type of tax information to be confidential. The confidential nature of this information was approved by the OEB in previous OPG proceedings (EB-2020-0290, Procedural Order No. 1, February 17, 2021, at p. 5; EB-2016-0152, Procedural Order No. 1, August 16, 2016, at p. 6; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p.3; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p.4) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit F4-2-1, Attachment 1, Part 5, Notices of Assessment – Hydro Payment in Lieu	All	Yes	Confidential Treatment	<p>Confidential, Non-public Financial Information of an Unregulated Affiliate Engaged in Competitive Business Activity: The Notices of Assessment – Hydro Payment in Lieu located at Exhibit F4-2-1, Attachment 1, Part 5 should be protected as confidential because it includes a significant amount of information that relates to the unregulated aspects of OPG’s business, both at the OPG corporate level and with respect to unregulated entities. This information is not relevant to this Application and OPG consistently treats it as confidential financial information (Practice Direction, Appendix A, Part (b); Appendix B, Part 5).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>Previous Treatment: The OEB has previously found this type of tax information to be confidential. The confidential nature of this information was approved by the OEB in previous OPG proceedings (EB-2020-0290, Procedural Order No. 1, February 17, 2021, at p. 5; EB-2016-0152, Procedural Order No. 1, August 16, 2016, at p. 6; EB-2013-0321, Procedural Order No. 4, March 21, 2014, at p.3; EB-2010-0008, Procedural Order No. 3, July 21, 2010, at p.4) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit F4-3-2, Attachment 1, Aon Report on OPG's Estimated Pension and OPEB Costs for 2025-2031	Page 37	No	Permanent Redaction for Non-Relevance	<p>Non-relevant: This information proposed for redaction consists of forward-looking total headcount data. The component parts of this data applicable to OPG's regulated business are included elsewhere in OPG's evidence (Exhibit A2-2-1, Attachment 1) and, where relevant, have not been marked for redaction or have been marked for confidential treatment, as the case may be. The total headcount data is marked for permanent redaction because disclosure of this aggregated information (combined with information regarding the regulated business already disclosed) would allow for the reverse engineering of headcount information with respect to OPG's unregulated subsidiaries engaged in competitive business activity. It is therefore not relevant to the determination of payment amounts in this proceeding (Practice Direction, Part 11).</p> <p>Commercially Sensitive Information and Competitive Prejudice: The headcount information related to OPG's subsidiaries is commercially sensitive, not available to the public, and treated as confidential by OPG and its subsidiaries. If disclosed on the public record it could prejudice OPG and its subsidiaries' competitive position (Practice Direction, Appendix A, Part (a)(i) and (b)).</p> <p>Previous Treatment: The OEB has previously determined that similar information related to OPG's unregulated business or that of its subsidiaries is not relevant to OPG's payment amounts applications (EB-2020-0290, Decision on Confidentiality, June 8, 2021, at pp. 2-3; EB-2016-0152, Procedural Order No. 3, at p. 4; EB-2013-0321, Procedural Order No. 4, at p. 6 and EB-2010-0008, Procedural Order No. 3, at p. 5) (Practice Direction, Appendix A, Part (e)).</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
Exhibit G2-1-1, Table 1	Page 1	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of revenue forecast for heavy water sales and processing, and isotope sales, in the period from 2025 to 2031. Confidential treatment is not being sought for historical actual revenue amounts (annual breakdown) or total revenue amounts.</p> <p>The redacted information is commercially sensitive, and it is kept confidential. The forecast for heavy water and isotope sales and proceeds concerns OPG's non-regulated business, where revenue depends on the forces of supply and demand in a limited market and a small number of potential transactions. Public disclosure of this information could be exploited by OPG counterparties by adjusting their strategy and negotiating position that would adversely impact OPG. As a result, disclosure could significantly interfere with current or future negotiations and prejudice OPG's competitive position in the market for heavy water and isotopes (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information about heavy water sales and proceeds should be subject to confidential treatment (EB-2020-0290, Decision on Confidential Filings – Pre-filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3; EB-2010-0008, Decision with Reasons, March 10, 2011, at p. 64;) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit G2-1-2, Tables 1a, 1b	Pages 1-2	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted consists of revenue forecast for heavy water sales and processing, and isotope sales, in the period from 2025 to 2031, including deltas presenting anticipated changes between actual revenue and forecast. Confidential treatment is not being sought for historical actual revenue amounts (annual breakdown) or total revenue amounts.</p> <p>The redacted information is commercially sensitive, and it is kept confidential. The forecast for heavy water and isotope sales and</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				<p>proceeds concerns OPG’s non-regulated business, where revenue depends on the forces of supply and demand in a limited market and a small number of potential transactions. Public disclosure of this information could be exploited by OPG counterparties by adjusting their strategy and negotiating position that would adversely impact OPG. Similarly, public disclosure of deltas would allow determination of the respective revenue forecast leading to the same undesirable outcome. As a result, disclosure could significantly interfere with current or future negotiations and prejudice OPG’s competitive position in the market for heavy water and isotopes (Practice Direction, Appendix A, Part (a)(i) and (iii)).</p> <p>Previous Treatment: The OEB has previously determined that information about heavy water sales and proceeds and other information that would allow determination of such sales and proceeds should be subject to confidential treatment (EB-2020-0290, Decision on Confidential Filings – Pre-filed Evidence, April 13, 2021, at p. 9; EB-2016-0152, Decision on Confidential Filings and Procedural Order No. 3, November 1, 2016, at p. 4; EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 3; EB-2010-0008, Decision with Reasons, March 10, 2011, at p. 64;) (Practice Direction, Appendix A, Part (e)).</p>
Exhibit H1-1-1, Attachment 3, Supporting Info for SBGVA Clearance re: EB-2023-0336, Ex. L-H-SEC-04, Attachment 1	Columns Q, R	No	Confidential Treatment	<p>Commercially Sensitive Information: The information redacted relates to efficiency increase information, which can be used to derive efficiency factors.</p> <p>The redacted information is commercially sensitive. Efficiency factors are kept confidential from competitors to OPG because this information would allow competitors to anticipate OPG’s bidding behavior in the electricity market, plan strategies, and adjust their own market offers accordingly in a way that could harm competition in the IESO administered market. As a result, disclosure of this information could prejudice OPG’s competitive position in the electricity market (Practice Direction, Appendix A, Part (a)(i)).</p> <p>Previous Treatment: The OEB has previously determined that information related to efficiency gains should be subject to confidential</p>

Appendix A

Exhibit Reference		Presumptive Confidential Treatment (Yes/No)	Type of Request ¹	Explanation and Rationale
				treatment (EB-2013-0321, Decision and Order on Confidential Filings and Procedural Order No. 4, March 21, 2014, at p. 5) (Practice Direction, Appendix A, Part (e)).

Appendix B – Unredacted Documents for OEB Review Only